KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Basic): 2009-2024

Historic EPS (Basic) for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $0.99.

  • Rigel Pharmaceuticals' EPS (Basic) rose 118.31% to $1.55 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.33, marking a year-over-year increase of 2652.17%. This contributed to the annual value of $0.99 for FY2024, which is 168.75% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its EPS (Basic) stood at $0.99 for FY2024, which was up 168.75% from -$1.44 recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' EPS (Basic) ranged from a high of $0.99 in FY2024 and a low of -$3.44 during FY2022.
  • In the last 3 years, Rigel Pharmaceuticals' EPS (Basic) had a median value of -$1.44 in 2023 and averaged -$1.30.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' EPS (Basic) crashed by 3,027.27% in 2022, and later skyrocketed by 168.75% in 2024.
  • Rigel Pharmaceuticals' EPS (Basic) (Yearly) stood at -$0.18 in 2020, then surged by 38.89% to -$0.11 in 2021, then plummeted by 3,027.27% to -$3.44 in 2022, then spiked by 58.14% to -$1.44 in 2023, then soared by 168.75% to $0.99 in 2024.